

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

**STA Alpelisib with fulvestrant for treating hormone
receptor-positive, HER2-negative, PIK3CA-mutated
advanced breast cancer [ID3929]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

No equality issues were identified during the scoping process.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

No equality issues have been raised in the submissions.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No equality issues have been identified by the committee.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other

groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No, currently there is a negative recommendation.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

Not applicable.

Approved by Associate Director (name): Henry Edwards

Date: 24/03/2022

Final appraisal determination

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

No equality issues were identified during the consultation process.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

The technology had a positive recommendation that is optimised based on previous treatment. People who have not received the specified previous treatment will not be eligible for the technology, but do have other treatment options.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

No.

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Yes, in section 3.25 of the FAD.

Approved by Associate Director (name): Henry Edwards

Date: 26/06/22